You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advancing a Glioma Immunotherapy
SBC: IN CYTU, INC. Topic: 102DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
A High Resolution Radiation Therapy Dosimetry system
SBC: DOSEIMAGING, LLC Topic: 399DESCRIPTION provided by applicant Modern radiation therapy treatment modalities such as intensity modulated radiation therapy are associated with complex dose distributions and sharp dose gradients Experimental dose validation using multidimensional high spatial resolution dosimeters is mandatory The product to be developed is a novel high resolution dosimetry system that combines reusabil ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
PEGYLATED PEPTIDES LIGANDS TARGETING RADIATION-INDUCIBLE RECEPTORS ON CANCER
SBC: Medical Guidance Systems LLC Topic: 102DESCRIPTION provided by applicant The proposed research is the study of new paradigms in both the treatment of cancer and cancer drug development This platform technology will markedly expand the number of cancer specific surface receptors and antigens that can be targeted for drug delivery using peptide ligands The general principle of this new technology is that cancer cells respond to ioni ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Carbon Fiber Off-Loading Orthosis
SBC: Orthotic & Prosthetic Design, Inc. Topic: 200DESCRIPTION provided by applicant This proposed project will further develop a CFC off loading AFO designed to offload plantar pressures and optimize patient function through maximizing plantarflexor power production During Phase I we will determine the effects of varying design characteristics of CFC off loading AFOs We will refine and create new FEA models and algorithms that predict the ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: RDESCRIPTION provided by applicant Noise is the most common occupational and environmental hazard thus it is not surprising that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit second only to age related hearing loss Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no medications approv ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza
SBC: EPIVAX, INC. Topic: NIAIDDESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans
SBC: INTACT GENOMICS INC Topic: RDESCRIPTION provided by applicant There is societal need for new therapeutic agents in our arsenal of defenses against bacterial and fungal pathogens many superbugs of which are increasingly resistant to existing antibiotics Filamentous fungi are considered promising resources for the development of novel bioactive compounds because of their great potential to produce various kinds of secon ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
IL2-based Immunotherapy for Type 2 Diabetes
SBC: APT THERAPEUTICS, INC. Topic: 200DESCRIPTION provided by applicant Principal Investigator Program Director Last First Middle Chen Ridong Abstract Type diabetes T D is a leading cause of cardiovascular disease renal failure blindness amputations and hospitalization Up to of T D patients are overweight or obese which induces chronic low grade inflammation of adipose tissue and promotes insulin resistance and T ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health